Product Description
Mechanisms of Action: GLP-2 Agonist
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Injection
FDA Designation: Orphan Drug - Graft vs Host Disease *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: 9 Meters Biopharma
Company Location: RALEIGH NC 27615
Company CEO: John Temperato
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Graft vs Host Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|